beta

AMRN

Amarin Corp. Plc

Amrn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Market Cap: 8.03 Billion

Primary Exchange: NASDAQ

Website: http://amarincorp.com

Shares Outstanding: 358 Million

Float: 352 Million

Dividend: (%)

Beta: 1.88521055590609

Sector: Health Technology

Industry: Pharmaceuticals: Other

Ethical Flags

Animal testing

Longest drawdown: 1422 trading days

From: 2013-01-17 To: 2018-09-21

Lowest Point:

Amarin Corporation plc (AMRN) CEO John Thero Presents at Goldman Sachs 40th Annual Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2019-06-12 17:43:08:000

Amarin Corporation plc (AMRN) Goldman Sachs 40th Annual Global Healthcare Conference Call June 12, 2019 4:20 P.M. ET Company Participants John Thero - President and Chief Executive Officer Conference Call Participants Presentation John Thero Hello, everybody. Thank you … read more...

BIIB Is For Buy-O-Gen

via: SeekingAlpha at 2019-06-12 06:30:36:000

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...

Upon Vascepa Expanded Label, The Landscape For Cardiovascular Disease Would Greatly Change

via: SeekingAlpha at 2019-06-11 16:54:13:000

Amarin ( AMRN ) is having good fortune, especially when it comes to its supplemental new drug application (sNDA) for its drug Vascepa. That's because the biotech is seeking to expand the label for approval of its drug to reduce cardiovascular risk for patients with statin-managed LDL-C chole… read more...

Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-09 03:30:00:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...

Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-09 03:30:00:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...

Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-09 03:30:00:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud